Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAN Body Mass Normalization of Oxaliplatin-Based Chemotherapy
2024-515340-23-00Phase 2Authorised
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Aug 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of oxaliplatin in colon cancer, sponsored by Institut du Cancer de Montpellier. Planned start Aug 2024; status: authorised.
02
Drugs
oxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2024-515340-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515340-23-00.